Singapore markets close in 6 hours 47 minutes

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.1100-0.0900 (-2.14%)
At close: 04:00PM EDT
3.9800 -0.13 (-3.16%)
After hours: 04:05PM EDT

Lyell Immunopharma, Inc.

201 Haskins Way
South San Francisco, CA 94080
United States
650 695 0677
https://www.lyell.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees219

Key executives

NameTitlePayExercisedYear born
Dr. Richard D. Klausner M.D.Founder & Exec. Chairman510.17kN/A1952
Ms. Elizabeth HomansCEO & Director988.85kN/A1966
Mr. Charles W. NewtonChief Financial Officer1.75MN/A1971
Mr. Stephen J. HillChief Operating Officer808.12kN/A1970
Ms. Heather D. TurnerChief Gen. Counsel & Sec.N/AN/A1973
Nellie DilleryDirector of AccountingN/AN/AN/A
Mr. Richard Goold Ph.D.Chief Information OfficerN/AN/A1960
Dr. Gary Lee Ph.D.Chief Scientific OfficerN/AN/A1977
Ellen RoseVP of Communications & Investor RelationsN/AN/AN/A
Ms. Lisa RyanChief People OfficerN/AN/A1967
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Corporate governance

Lyell Immunopharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.